Gastric adenocarcinoma with a yolk sac component: a case report and review of the literature.

Gastric yolk sac tumors (YST) are very rare and are mainly reported in elderly people. We present a case of a 36-year-old man with a poorly differentiated gastric cancer showing a mixture of adenocarcinoma and yolk sac tumor that metastasized to Virchow's node. Both biopsies, Virchow's node and gastric tumor, contained areas of adenocarcinoma and yolk sac tumor that stained strongly positive for alpha fetoprotein (AFP) by the immunohistochemistry method.

Clinically silent primary adrenal lymphoma: a case report and review of the literature.

Primary adrenal lymphoma (PAL) is extremely uncommon. We describe a case of clinically silent non-Hodgkin's B-cell lymphoma of diffuse large cell type with exclusive left adrenal localization. The tumor was discovered by computed tomography (CT) as a 2.

The pathogenesis and prevention of thromboembolic complications in patients undergoing total hip replacement.

A 1987 survey of U.S. orthopedic surgeons found that 84% used some form of DVT prophylaxis.

Prolonged survival with unresected pulmonary metastases.

The cases of 3 selected patients who had prolonged survival with pulmonary metastases that doubled in size yearly are reported. The experience with these patients and another, whose disease rapidly progressed after resection of pulmonary metastases, admonishes that the selection criteria for resection of pulmonary metastases require further refinement.

Chemotherapy of unresectable or recurrent metastatic malignant melanomas: an update.

Satisfactory chemotherapeutic management of malignant melanomas in advanced stages must await development of more active agents and combinations of them than are presently available. The development of entirely new means of treatment by hormones, heat, and adjuvants like amphotericin B may improve the efficacy of currently available agents.

Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.

One hundred and thirty-four patients with advanced malignant disease were treated with 496 infusions of high-dose methotrexate (HD-MTX) followed by citrovorum factor rescue. Most patients had failed to respond to previous combination chemotherapy. The overall response rate was 29% with 33 partial responses and six complete responses observed in patients with a variety of tumors.